Skip to main content
padlock icon - secure page this page is secure

Prophylaxis of chemotherapy‐induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non‐Hodgkin lymphoma (NADIR study)

Buy Article:

$59.00 + tax (Refund Policy)

The prospective non‐interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex®), a glycopegylated granulocyte colony‐stimulating factor, in cancer patients with different tumor entities undergoing chemotherapy in routine clinical practice. The primary objective was incidence of severe neutropenia, febrile neutropenia (FN), and neutropenia‐associated complications.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: chemotherapy‐induced febrile neutropenia; granulocyte colony‐stimulating factor; lipegfilgrastim; non‐Hodgkin lymphoma; primary prophylaxis; routine clinical practice

Document Type: Research Article

Publication date: February 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more